Precision Medicine Approaches to Renal Osteodystrophy

Recruiting now

Conditions studied: Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism

In brief

Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not practical in the clinic for the vast majority of kidney disease patients and parathyroid hormone and bone alkaline phosphatase have insufficient accuracy for turnover type to safely and confidently guide treatment of renal osteodystrophy. In the present investigation, the investigators will study a microRNA approach as a novel non-invasive biomarker of turnover for renal osteodystrophy.

Key facts

Study ID

NCT05880914

Run by

Thomas Nickolas

People needed

40

Starts

2022-12-21

Expected to finish

2027-06-30

Last updated by the study team

2026-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Study participant has provided informed consent
• Age ≥ 18 years
• CKD Stages 3-5D regardless of kidney transplantation status
• CKD5D patients receiving maintenance hemodialysis for at least 3 months
• Clinically indicated treatment for renal hyperparathyroidism, renal osteodystrophy and/or Osteoporosis
• PTH, BSAP and CTX meets defined thresholds for low or high turnover ROD type or a Bone biopsy evidence of low or high turnover based

You may not qualify if…

• Currently receiving treatment in an investigational device or drug study, or less than 30 days since ending treatment on an investigational device or drug study(s)
• Currently receiving investigational procedures/drugs from another study while participating in this study
• Use of etelcalcetide, bisphosphonate, denosumab, teriparatide, abaloparatide or romosozumab during the 6 months prior to study enrollment; however, participant can be included if being treated with bone active agent but will have class change to an agent that will result in a change in bone turnover from low to high or high to low
• New use of cinacalcet over the prior 6 months
• Use of Zoledronic Acid (Reclast) less than 24 months from study enrollment for patients with eGFR <30mL/minute
• Anticipated or scheduled kidney transplant during the study period or less than 1 year from receiving a kidney transplant
• For patients with a solid organ transplant, less than 1 year from receiving the transplant
• Patient has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator
• Metabolic bone diseases not related to the kidney (e.g., Paget's, Osteogenesis Imperfecta)
• Endocrinopathy (e.g., untreated hyperthyroidism)
• Malignancy within the last 5 years (except non-melanoma skin cancers or cervical carcinoma in situ)
• Patient is pregnant or nursing
• Weight >300 pounds (scanner limitation)
• Allergy to tetracycline or demeclocycline
• Patients on non-aspirin anticoagulants that cannot be reasonably held for biopsy
• Patient unable to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the patient and Investigator's knowledge

Where it is running

• Washington University in St. Louis (WashU) — St Louis, Missouri, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.